Kaya Holdings, Inc. KAYS OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score

25/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Kaya Holdings, Inc. (KAYS) .

Criteria proven by this page:

VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.

Overall SharesGrow Score: 24/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

25/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

PAST

50/100

→ Income

HEALTH

50/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

0/100

→ Income

✗

GROWTH

15/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — KAYS

Valuation Multiples

P/E (TTM)0.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio1,137.95

EV/EBITDA0.0

Per Share Data

EPS (TTM)$-0.07

Book Value / Share$0.00

Revenue / Share$0.00

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Dividend Yield0.00%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2015	$-0.56	$323.92K	$-3.23M	-995.6%
2016	$-2.92	$952.85K	$-19.85M	-2083.1%
2017	$-1.74	$966.38K	$-14.88M	-1540%
2018	$0.42	$1.14M	$4.75M	417.5%
2019	$0.30	$1.01M	$7.8M	769.6%
2020	$-0.92	$1.03M	$-12.1M	-1174.7%
2021	$0.13	$889.9K	$9.72M	1092.7%
2022	$-0.24	$685.38K	$-3.58M	-521.9%
2023	$0.01	$196.29K	$1.61M	820.2%
2024	$-0.07	$7.13K	$-2.08M	-29170.2%